head and neck cancer Nov 3, 2022 Kura Oncology Receives $25M Investment From Bristol Myers Squibb; Enters $125M Loan Agreement Sep 29, 2022 New NIH-Funded Network Aims to Bring Precision to External Beam Radiation Treatment Premium Sep 28, 2022 Cofactor Genomics RNA-seq Assay Outperforms PD-L1 IHC to Predict Immunotherapy Responders Premium Sep 19, 2022 Naveris Nabs $33.4M Series A Round Expansion to Further Commercialize Virus-Related Cancer Tests Jul 27, 2022 Nutcracker Therapeutics Aims to Beat HPV-Driven Cancers With Multimodal mRNA Therapeutics Premium Jul 11, 2022 Immune Checkpoint Blockade Response Linked to Recurrent Mutations in Genes, Pathways Jul 6, 2022 Bio-Techne Nabs CE Mark for HPV Head and Neck Cancer Test, Completes Namocell Acquisition May 11, 2022 FDA Accepts Cue Biopharma's IND for CUE-102 in WT1-Expressing Cancers Apr 20, 2022 BeiGene Updates Phase III Data, Biomarker Analysis for Anti-PD-1 Drug in Nasopharyngeal Cancer Apr 19, 2022 PDS Biotechnology Nets $1.2M Through NJ Economic Development Program to Advance Oncology Candidates Feb 17, 2022 New Data Further Validates Inivata's MRD Test as Company Prepares Commercial Launch Premium Feb 15, 2022 Mayo Clinic Exploring PDS Biotech's PDS0101, Merck's Keytruda in HPV-Associated Oropharyngeal Cancer Feb 11, 2022 Seattle Cancer Care Alliance Aims to Improve Molecular Profiling Access for Thyroid Cancer Patients Premium Dec 16, 2021 Kura Oncology Begins Trial of Tipifarnib, Novartis' Piqray in Head and Neck Cancer Dec 3, 2021 I-Mab Begins Study of Uliledlimab Plus Tecentriq in Advanced Solid Tumors Aug 19, 2021 TERT Promoter Mutations Linked to Higher Recurrence Risk in Oral Cavity Cancers Premium Jul 16, 2021 In Brief This Week: Strata Oncology, Ideaya Biosciences, Children's Cancer Institute Australia, BMS Jul 6, 2021 Novartis, Kura Oncology Partner on Phase I/II Head and Neck Cancer Study of Piqray, Tipifarnib Apr 15, 2021 OncoDNA, Institut Curie Partner on Liquid Biopsy Research in Head and Neck Cancer Apr 13, 2021 Cofactor Genomics Begins Multi-Site Clinical Trial for Immunotherapy Prediction Assay Load More Breaking News Apollomics Completes SPAC Merger, Begins Public Trading on Nasdaq Ablaze Pharmaceuticals to Develop RayzeBio's GPC3-Targeted Radiotherapy In Brief This Week: Allarity Therapeutics, Immutep, Thermo Fisher Scientific EMA's CHMP Recommends BMS's Breyanzi as Second-Line Lymphoma Treatment Exai Bio, Quantum Leap Healthcare Collaborative Expand Participation in RNA Liquid Biopsy Trial Omega Therapeutics, Roche Partner for Phase I/II Trial in MYC-Driven Hepatocellular Carcinoma
